Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity DOI Creative Commons

Maya Haus‐Cohen,

Yoram Reiter

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 22, 2024

The clinical success of cancer immunotherapy has driven ongoing efforts to identify novel targets that can effectively guide potent effector functions eliminate malignant cells. Traditionally, immunotherapies have focused on surface antigens; however, these represent only a small fraction the proteome, limiting their therapeutic potential. In contrast, majority proteins within human proteome are intracellular, yet they represented cell as short peptides presented by MHC class I molecules. These peptide-MHC complexes offer vast and largely untapped resource for targets. intracellular including neo-antigens, presents an exciting opportunity development cell-based soluble immunotherapies. Targeting intracellular-derived molecules surfaces be achieved using specific T-cell receptors (TCRs) or TCR-mimicking antibodies, known TCR-like (TCRL) antibodies. Current strategies under investigation include adoptive transfer TCR-engineered TCRL-T cells CAR-T target complexes, well TCR- TCRL-based agents like bispecific T engagers. Recent developments in targeting TCRL- TCR-based shown promising results, with two therapies recently receiving FDA approval treatment unresectable metastatic uveal melanoma synovial sarcoma. This review focuses processes selecting isolating moieties, emphasis pre-clinical studies explore potential immunotherapy.

Language: Английский

Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer DOI Creative Commons

Yizhao Chen,

Qianling Xin,

Mengjuan Zhu

et al.

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

After significant advancements in tumor treatment, personalized cell therapy based on chimeric antigen receptors (CAR) holds promise for transforming the management of various diseases. CAR-T therapy, first approved CAR product, has demonstrated therapeutic potential treating infectious diseases, autoimmune disorders, and fibrosis. CAR-macrophages (CAR-Ms) are emerging as a promising approach immune particularly solid highlighting feasibility using macrophages to eliminate pathogens abnormal cells.

Language: Английский

Citations

1
Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity DOI Creative Commons

Maya Haus‐Cohen,

Yoram Reiter

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 22, 2024

The clinical success of cancer immunotherapy has driven ongoing efforts to identify novel targets that can effectively guide potent effector functions eliminate malignant cells. Traditionally, immunotherapies have focused on surface antigens; however, these represent only a small fraction the proteome, limiting their therapeutic potential. In contrast, majority proteins within human proteome are intracellular, yet they represented cell as short peptides presented by MHC class I molecules. These peptide-MHC complexes offer vast and largely untapped resource for targets. intracellular including neo-antigens, presents an exciting opportunity development cell-based soluble immunotherapies. Targeting intracellular-derived molecules surfaces be achieved using specific T-cell receptors (TCRs) or TCR-mimicking antibodies, known TCR-like (TCRL) antibodies. Current strategies under investigation include adoptive transfer TCR-engineered TCRL-T cells CAR-T target complexes, well TCR- TCRL-based agents like bispecific T engagers. Recent developments in targeting TCRL- TCR-based shown promising results, with two therapies recently receiving FDA approval treatment unresectable metastatic uveal melanoma synovial sarcoma. This review focuses processes selecting isolating moieties, emphasis pre-clinical studies explore potential immunotherapy.

Language: Английский

Citations

0